Zynex, Inc. specializes in non-invasive pain management and patient monitoring, with promising advancements like the NiCO pulse oximeter targeting accurate readings for diverse skin tones. Despite ...

Zynex (NASDAQ:ZYXI – Get Free Report) had its price objective lowered by equities researchers at HC Wainwright from $17.00 to $15.00 in a research note issued on Wednesday,Benzinga reports.

Good afternoon, ladies and gentlemen, and welcome to the Zynex fourth-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now ...

Zynex Inc. (ZYXI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.04 per share a year ago. These figures are ...

Zynex (NASDAQ:ZYXI) shares plunged in the premarket on Wednesday after the nerve stimulation product maker missed Street forecasts with its Q4 2024 financials, prompting RBC Capital Markets to ...

RBC Capital downgraded Zynex (ZYXI) to Sector Perform from Outperform with a price target of $5.50, down from $11. The firm says the company’s “disappointing update” on its Q4 earnings call ...

Ladenburg downgraded Zynex (ZYXI) to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue pressure. Effectively assess a stock's risks and ...

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s possible violations of ...